<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227629</url>
  </required_header>
  <id_info>
    <org_study_id>1160.20</org_study_id>
    <secondary_id>PETRO trial</secondary_id>
    <nct_id>NCT01227629</nct_id>
  </id_info>
  <brief_title>PETRO Stroke Prevention in Patients With AF by Treatment With Dabigatran, With and Without Aspirin, Compared to Warfarin</brief_title>
  <official_title>Dose Exploration in Patients With Atrial Fibrillation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      The purpose of this trial is to evaluate the safety of different doses of BIBR 1048, alone or
      in combination with acetylsalicylic acid (ASA), as determined by the rates of bleeding and
      other adverse events.

      A secondary objective of this trial is to evaluate the anticoagulant effect of different
      doses of BIBR 1048, based on the reduction of plasma concentrations of D-dimer, a laboratory
      marker for activated coagulation in patients with atrial fibrillation (AF), and to correlate
      bleeding and other events with pharmacokinetic (PK) and pharmacodynamic (PD) data.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Fatal or Life-threatening Major Bleeding Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Retroperitoneal, intracranial, intraocular, or intraspinal bleeding, or requiring surgical treatment, or leading to a transfusion of 2 units or more, or leading to a fall in hemoglobin of 20g/L or more</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Minor/Relevant Bleeding Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Haematuria, rectal bleeding, gingival bleeding, skin hematoma of 25cm^2 or more, nose bleed of more than 5 minutes duration, bleeding leading to a hospitalization, leading to a transfusion of less than 2 units or any other clinically relevant bleeding</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Minor/Nuisance Bleeding Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>All bleeding events not fulfilling one of the criteria for major bleeding event or minor/relevant bleeding events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thromboembolic Events: Composite Endpoint</measure>
    <time_frame>12 weeks</time_frame>
    <description>Combination of ischemic stroke (fatal or non fatal), transient ischemic attack, systemic thromboembolism, myocardial infarction (fatal or non fatal), other major adverse cardiac event and all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Thromboembolic Events: Ischemic Stroke</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurence of an ischemic stroke (fatal or non-fatal)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic Events: Number of Participants With Transient Ischemic Attack</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurence of a transient ischemic attack</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic Events: Number of Participants With Systemic Thromboembolism</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurence of a systemic thromboembolism</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic Events: Number of Participants With Myocardial Infarction</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurence of a myocardial infarction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic Events: Number of Participants With Other Major Cardiac Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurence of other major adverse cardiac events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thromboembolic Events: Number of Participants Who Died</measure>
    <time_frame>12 weeks</time_frame>
    <description>Occurence of death by all causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>D-dimer: Difference From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Difference in D-dimer from baseline to last available value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Soluble Fibrin: Difference From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Difference from baseline to visit 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>11-dehydrothromboxane B2 (TXB2): Difference From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
    <description>Difference from baseline to visit 7</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ecarin Clotting Time (ECT): Difference From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Activated Partial Thromboplastin Time (aPTT): Difference From Baseline</measure>
    <time_frame>baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Plasma Concentration of Dabigatran (BIBR 953)</measure>
    <time_frame>12 weeks</time_frame>
    <description>The values of the trough plasma concentration of dabigatran (BIBR 953) are the by-patient geometric means of week 1, 4 and 12.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase of Aspartat-Aminotransferase (AST) to &gt;2*Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Increase of AST to more than two times the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase of Alkaline Phosphatase (AP) to &gt;2*Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Increase of AP to more than two times the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase of Bilirubin to &gt;2*Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Increase of Bilirubin to more than two times the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Increase of Alanine-Aminotransferase (ALT) to &gt;2*Baseline</measure>
    <time_frame>12 weeks</time_frame>
    <description>Number of Participants with Increase of ALT to more than two times the baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severity of Adverse Events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Total number of patients with any adverse event of worst intensity 'mild', 'moderate' and 'severe'.</description>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">502</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>dabigatran 50 mg twice daily (bid)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening. Twice daily (bis in die = bid).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran 50 mg bid + 81 mg ASA qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening. Acetylsalicylic acid (ASA) once daily (quaque dies = qd) in the morning.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran 50 mg bid + 325 mg ASA qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran 150 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran 150 mg bid + 81 mg ASA qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran 150 mg bid + 325 mg ASA qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran 300 mg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran 300 mg bid + 81 mg ASA qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>dabigatran 300 mg bid + 325 mg ASA qd</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dabigatran: one capsule in the morning and 1 capsule in the evening. ASA in the morning</description>
  </arm_group>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>once daily, dosed to target International Normalised Ratio (INR) 2.0 to 3.0</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran with ASA</intervention_name>
    <description>dose comparison in combination</description>
    <arm_group_label>dabigatran 50 mg bid + 81 mg ASA qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran with ASA</intervention_name>
    <description>dose comparison in combination</description>
    <arm_group_label>dabigatran 50 mg bid + 325 mg ASA qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran with ASA</intervention_name>
    <description>dose comparison in combination</description>
    <arm_group_label>dabigatran 150 mg bid + 81 mg ASA qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran with ASA</intervention_name>
    <description>dose comparison in combination</description>
    <arm_group_label>dabigatran 150 mg bid + 325 mg ASA qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran with ASA</intervention_name>
    <description>dose comparison in combination</description>
    <arm_group_label>dabigatran 300 mg bid + 81 mg ASA qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran with ASA</intervention_name>
    <description>dose comparison in combination</description>
    <arm_group_label>dabigatran 300 mg bid + 325 mg ASA qd</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <description>comparator</description>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran without ASA</intervention_name>
    <description>dose comparison</description>
    <arm_group_label>dabigatran 50 mg twice daily (bid)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran without ASA</intervention_name>
    <description>dose comparison</description>
    <arm_group_label>dabigatran 150 mg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dabigatran without ASA</intervention_name>
    <description>dose comparison</description>
    <arm_group_label>dabigatran 300 mg bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria

          1. Non-rheumatic atrial fibrillation.

          2. Coronary artery disease (CAD), documented by previous myocard infarction (MI), angina,
             positive stress test, previous coronary intervention or bypass surgery, or
             atherosclerotic lesion(s) diagnosed by coronary angiography) is only considered as one
             of several possible qualifying risk factors. After recruitment of ca. 30%, a protocol
             amendment 4 was issued so that CAD was only considered as one of several possible
             qualifying risk factors, 2. see (3 f) below.

          3. An additional risk factor for stroke, i.e. one or more of the following
             conditions/events:

               1. hypertension (defined as systolic bloodpressure (SBP) &gt; 140 mmHg and/or diastolic
                  bloodpressure (DBP) &gt; 90 mm Hg) requiring antihypertensive medical treatment.

               2. diabetes mellitus (type I and II).

               3. symptomatic heart failure or left ventricular dysfunction (ejection fraction (EF)
                  &lt; 40%).

               4. a previous ischemic stroke or transient ischemic attack.

               5. age greater than 75 years.

               6. history of coronary artery disease (by amendment 4)

          4. Treatment with warfarin or other vitamin K dependent anticoagulants for at least 8
             weeks prior to inclusion. International normalised ratio (INR) should be within
             therapeutic range (i.e. INR 2.0 - 3.0) at visit 1 otherwise the visit should be
             rescheduled.

          5. Age &gt; = 18 years at entry.

          6. Written, informed consent.

        Exclusion criteria

          1. Valvular heart disease.

          2. Planned cardioversion.

          3. Recent (=&lt; 1 month) myocardial infarction, stroke or transient ischemic attack (TIA),
             or patients who have received a coronary stent within the last 6 months.

          4. Intolerance or contraindications to acetylsalicylic acid (ASA).

          5. Any contraindication to anticoagulant therapy.

          6. Major bleeding within the last 6 months (other than gastrointestinal (GI) hemorrhage).

          7. Severe renal impairment (estimated glomerular filtration rate (GFR) =&lt; 30 mL/min).

          8. Uncontrolled hypertension (SBP &gt; 180 mmHg and/or DBP &gt; 100 mmHg).

          9. Abnormal liver function as defined by aspartat-aminotransferase (AST),
             alanin-aminotransferase (ALT), serum bilirubin or alkaline phosphatase (AP) above the
             reference range, or history of liver disease.

         10. Women who are pregnant or of childbearing potential who refuses to use a medically
             acceptable form of contraception throughout the study.

         11. Patients who have received an investigational drug within the last 30 days.

         12. Patients scheduled for major surgery or invasive procedures which may cause bleeding,
             or those who have had major surgery or percutaneous coronary intervention (PCI) within
             6 weeks.

         13. Patients considered unreliable by the investigator.

         14. Another indication for anticoagulant treatment.

         15. Patients suffering from anemia.

         16. Patients suffering from thrombocytopenia.

         17. Any other condition which, in the discretion of the investigator, would not allow safe
             participation in the study.

         18. Concomitant treatment with antiplatelet agents other than ASA.

         19. Recent malignancy or radiation therapy (=&lt; 6 month).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1160.20.10010</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10003 La Mesa Cardiac</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10006 The Ford Research Institute, PA</name>
      <address>
        <city>Pensacola</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10004</name>
      <address>
        <city>Port Charlotte</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10002</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10015</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10008</name>
      <address>
        <city>Westminister</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10012</name>
      <address>
        <city>Pittsfield</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10007</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10014</name>
      <address>
        <city>Hawthorne</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10013</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10009</name>
      <address>
        <city>North Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10001</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.10005</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45010</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45005 Aarhus Sygehus</name>
      <address>
        <city>Aarhus C</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45007 Medicinsk afdeling</name>
      <address>
        <city>Brædstrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45011 Medicinsk afd.</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45012 Afdeling B3</name>
      <address>
        <city>Frederikssund</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45003 Forskningscentret plan 3</name>
      <address>
        <city>Helsingør</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45004 Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45009 Medicinsk amb. B8</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45002 Kardiologisk afdeling</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45014 Hjertemedicinsk afd.</name>
      <address>
        <city>Køge</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45001 Kardiologisk Laboratorium</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45013 Kardiologisk afd.</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.45006 Medicinsk afdeling</name>
      <address>
        <city>Svendborg</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46013 HIA, Mälarsjukhuset</name>
      <address>
        <city>Eskilstuna</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46007 Falu Lasarett</name>
      <address>
        <city>Falun</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46005 Ryhovs Länssjukhus</name>
      <address>
        <city>Jönköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46010 Länssjukhuset Kalmar</name>
      <address>
        <city>Kalmar</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46009 Universitetssjukhuset MAS</name>
      <address>
        <city>Malmö</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46008 Vrinnevisjukhuset</name>
      <address>
        <city>Norrköping</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46002 Södersjukhuset</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46011 Arytmienheten, Med klin</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46006 Norrlands Universitetssjukhus</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46003 Centrallasarettet</name>
      <address>
        <city>Västerås</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1160.20.46004 Universitetssjukhuset</name>
      <address>
        <city>Örebro</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2010</study_first_submitted>
  <study_first_submitted_qc>October 22, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>November 18, 2010</results_first_submitted>
  <results_first_submitted_qc>January 14, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2011</results_first_posted>
  <last_update_submitted>April 22, 2014</last_update_submitted>
  <last_update_submitted_qc>April 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 5, 2014</last_update_posted>
  <responsible_party>
    <name_title>Boehringer Ingelheim, Study Chair</name_title>
    <organization>Boehringer Ingelheim</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warfarin</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>BIBR 1048 50 mg b.i.d</title>
          <description>bid (twice daily) oral</description>
        </group>
        <group group_id="P2">
          <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="P3">
          <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="P4">
          <title>BIBR 1048 150 mg b.i.d</title>
          <description>bid (twice daily) oral</description>
        </group>
        <group group_id="P5">
          <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="P6">
          <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="P7">
          <title>BIBR 1048 300 mg b.i.d</title>
          <description>bid (twice daily) oral</description>
        </group>
        <group group_id="P8">
          <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="P9">
          <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="P10">
          <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
          <description>qd (once daily) oral</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="58">Started: Participant was randomised and took at least one dose of randomised study medication</participants>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="99"/>
                <participants group_id="P5" count="34"/>
                <participants group_id="P6" count="33"/>
                <participants group_id="P7" count="98"/>
                <participants group_id="P8" count="33"/>
                <participants group_id="P9" count="30"/>
                <participants group_id="P10" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="56">Completed: Participant without premature discontinuation in the randomised treatment period</participants>
                <participants group_id="P2" count="18"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="91"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="32"/>
                <participants group_id="P7" count="90"/>
                <participants group_id="P8" count="27"/>
                <participants group_id="P9" count="24"/>
                <participants group_id="P10" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="8"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
                <participants group_id="P10" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not Specified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BIBR 1048 50 mg b.i.d</title>
          <description>bid (twice daily) oral</description>
        </group>
        <group group_id="B2">
          <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="B3">
          <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="B4">
          <title>BIBR 1048 150 mg b.i.d</title>
          <description>bid (twice daily) oral</description>
        </group>
        <group group_id="B5">
          <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="B6">
          <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="B7">
          <title>BIBR 1048 300 mg b.i.d</title>
          <description>bid (twice daily) oral</description>
        </group>
        <group group_id="B8">
          <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="B9">
          <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
          <description>bid (twice daily) oral + qd (once daily) oral</description>
        </group>
        <group group_id="B10">
          <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
          <description>qd (once daily) oral</description>
        </group>
        <group group_id="B11">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="58"/>
            <count group_id="B2" value="20"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="99"/>
            <count group_id="B5" value="34"/>
            <count group_id="B6" value="33"/>
            <count group_id="B7" value="98"/>
            <count group_id="B8" value="33"/>
            <count group_id="B9" value="30"/>
            <count group_id="B10" value="70"/>
            <count group_id="B11" value="502"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.0" spread="8.8"/>
                    <measurement group_id="B2" value="70.1" spread="9.4"/>
                    <measurement group_id="B3" value="71.6" spread="8.1"/>
                    <measurement group_id="B4" value="69.7" spread="7.7"/>
                    <measurement group_id="B5" value="72.1" spread="9.0"/>
                    <measurement group_id="B6" value="69.7" spread="8.0"/>
                    <measurement group_id="B7" value="69.0" spread="9.1"/>
                    <measurement group_id="B8" value="71.8" spread="7.2"/>
                    <measurement group_id="B9" value="68.6" spread="7.1"/>
                    <measurement group_id="B10" value="69.0" spread="8.3"/>
                    <measurement group_id="B11" value="69.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="19"/>
                    <measurement group_id="B8" value="7"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="84"/>
                    <measurement group_id="B5" value="26"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="79"/>
                    <measurement group_id="B8" value="26"/>
                    <measurement group_id="B9" value="28"/>
                    <measurement group_id="B10" value="59"/>
                    <measurement group_id="B11" value="411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline documentation regarding the atrial fibrillation</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Persistent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="43"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="10"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="27"/>
                    <measurement group_id="B11" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Permanent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="35"/>
                    <measurement group_id="B5" value="11"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="10"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="26"/>
                    <measurement group_id="B11" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Paroxysmal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="7"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="9"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="17"/>
                    <measurement group_id="B11" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline documentation regarding stroke</title>
          <description>Documentation of stroke as specific risk factor</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="93"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="91"/>
                    <measurement group_id="B8" value="31"/>
                    <measurement group_id="B9" value="26"/>
                    <measurement group_id="B10" value="62"/>
                    <measurement group_id="B11" value="459"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="7"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline documentation regarding transient ischemic attack</title>
          <description>Documentation of transient ischemic attack as specific risk factor</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="88"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="31"/>
                    <measurement group_id="B7" value="90"/>
                    <measurement group_id="B8" value="30"/>
                    <measurement group_id="B9" value="26"/>
                    <measurement group_id="B10" value="63"/>
                    <measurement group_id="B11" value="453"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="8"/>
                    <measurement group_id="B8" value="3"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="7"/>
                    <measurement group_id="B11" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline documentation regarding transient ischemic attack or stroke</title>
          <description>Documentation of transient ischemic attack or stroke as specific risk factor</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="82"/>
                    <measurement group_id="B5" value="27"/>
                    <measurement group_id="B6" value="28"/>
                    <measurement group_id="B7" value="85"/>
                    <measurement group_id="B8" value="28"/>
                    <measurement group_id="B9" value="22"/>
                    <measurement group_id="B10" value="57"/>
                    <measurement group_id="B11" value="415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="17"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="13"/>
                    <measurement group_id="B11" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline documentation regarding hypertension</title>
          <description>Documentation of hypertension as specific risk factor</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="8"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="21"/>
                    <measurement group_id="B11" value="146"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="74"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="49"/>
                    <measurement group_id="B11" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline documentation regarding symptomatic heart failure</title>
          <description>Documentation of symptomatic heart failure as specific risk factor</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="73"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="85"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="46"/>
                    <measurement group_id="B11" value="355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="13"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="24"/>
                    <measurement group_id="B11" value="147"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline documentation regarding left ventricular dysfunction</title>
          <description>Documentation of left ventricular dysfunction as specific risk factor</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="68"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="78"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="14"/>
                    <measurement group_id="B10" value="44"/>
                    <measurement group_id="B11" value="337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="12"/>
                    <measurement group_id="B6" value="14"/>
                    <measurement group_id="B7" value="20"/>
                    <measurement group_id="B8" value="13"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="26"/>
                    <measurement group_id="B11" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline documentation regarding symptomatic heart failure or left ventricular dysfunction</title>
          <description>Documentation of symptomatic heart failure or left ventricular dysfunction as specific risk factor</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="17"/>
                    <measurement group_id="B7" value="71"/>
                    <measurement group_id="B8" value="14"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="34"/>
                    <measurement group_id="B11" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="19"/>
                    <measurement group_id="B6" value="16"/>
                    <measurement group_id="B7" value="27"/>
                    <measurement group_id="B8" value="19"/>
                    <measurement group_id="B9" value="18"/>
                    <measurement group_id="B10" value="36"/>
                    <measurement group_id="B11" value="225"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Coronary Artery Disease</title>
          <description>Documentation of Coronary Artery Disease as inclusion criterion or specific risk factor</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>no</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="4"/>
                    <measurement group_id="B7" value="62"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="28"/>
                    <measurement group_id="B11" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="44"/>
                    <measurement group_id="B5" value="31"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="36"/>
                    <measurement group_id="B8" value="31"/>
                    <measurement group_id="B9" value="29"/>
                    <measurement group_id="B10" value="42"/>
                    <measurement group_id="B11" value="306"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>D-dimer at baseline N=(56;19;25;88;29;32;85;31;29;63;457)</title>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="106.8" spread="104.1"/>
                    <measurement group_id="B2" value="104.5" spread="62.9"/>
                    <measurement group_id="B3" value="176.9" spread="389.9"/>
                    <measurement group_id="B4" value="100.8" spread="94.5"/>
                    <measurement group_id="B5" value="120.3" spread="95.4"/>
                    <measurement group_id="B6" value="96.3" spread="64.3"/>
                    <measurement group_id="B7" value="146.8" spread="210.9"/>
                    <measurement group_id="B8" value="119.4" spread="95.5"/>
                    <measurement group_id="B9" value="83.8" spread="48.8"/>
                    <measurement group_id="B10" value="139.9" spread="251.9"/>
                    <measurement group_id="B11" value="120.9" spread="173.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Soluble fibrin at baseline N=(53;16;23;88;27;29;92;30;25;65;448)</title>
          <units>µg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="4.4"/>
                    <measurement group_id="B2" value="5.3" spread="7.9"/>
                    <measurement group_id="B3" value="5.4" spread="5.9"/>
                    <measurement group_id="B4" value="5.8" spread="8.8"/>
                    <measurement group_id="B5" value="9.1" spread="15.5"/>
                    <measurement group_id="B6" value="7.6" spread="14.8"/>
                    <measurement group_id="B7" value="7.4" spread="11.5"/>
                    <measurement group_id="B8" value="9.2" spread="26.0"/>
                    <measurement group_id="B9" value="6.5" spread="9.2"/>
                    <measurement group_id="B10" value="7.2" spread="10.4"/>
                    <measurement group_id="B11" value="6.8" spread="11.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Thromboxane B2 (TXB2) measured at baseline N=(53;20;23;93;30;30;90;31;30;67;467)</title>
          <units>pg/mg Creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3968.5" spread="2530.4"/>
                    <measurement group_id="B2" value="3795.9" spread="2252.9"/>
                    <measurement group_id="B3" value="4705.6" spread="3047.5"/>
                    <measurement group_id="B4" value="4138.1" spread="2184.6"/>
                    <measurement group_id="B5" value="4485.7" spread="2147.8"/>
                    <measurement group_id="B6" value="4084.9" spread="2253.5"/>
                    <measurement group_id="B7" value="3619.0" spread="2020.6"/>
                    <measurement group_id="B8" value="4450.8" spread="2653.7"/>
                    <measurement group_id="B9" value="3735.6" spread="2440.6"/>
                    <measurement group_id="B10" value="4177.9" spread="2661.2"/>
                    <measurement group_id="B11" value="4051.6" spread="2367.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECT at baseline N=(57;20;27;98;34;33;95;33;29;56;482)</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" spread="2.0"/>
                    <measurement group_id="B2" value="31.8" spread="1.9"/>
                    <measurement group_id="B3" value="31.9" spread="2.2"/>
                    <measurement group_id="B4" value="31.9" spread="2.2"/>
                    <measurement group_id="B5" value="32.0" spread="1.9"/>
                    <measurement group_id="B6" value="32.6" spread="2.4"/>
                    <measurement group_id="B7" value="33.6" spread="13.3"/>
                    <measurement group_id="B8" value="31.9" spread="1.8"/>
                    <measurement group_id="B9" value="32.2" spread="2.6"/>
                    <measurement group_id="B10" value="32.0" spread="2.4"/>
                    <measurement group_id="B11" value="32.4" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>aPTT at baseline N=(57;20;27;98;34;33;96;33;29;57;484)</title>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.5" spread="3.0"/>
                    <measurement group_id="B2" value="31.2" spread="3.5"/>
                    <measurement group_id="B3" value="32.4" spread="3.6"/>
                    <measurement group_id="B4" value="34.2" spread="15.2"/>
                    <measurement group_id="B5" value="33.5" spread="7.6"/>
                    <measurement group_id="B6" value="34.2" spread="6.7"/>
                    <measurement group_id="B7" value="32.8" spread="5.7"/>
                    <measurement group_id="B8" value="32.6" spread="3.4"/>
                    <measurement group_id="B9" value="32.9" spread="6.7"/>
                    <measurement group_id="B10" value="33.2" spread="3.7"/>
                    <measurement group_id="B11" value="33.1" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Fatal or Life-threatening Major Bleeding Events</title>
        <description>Retroperitoneal, intracranial, intraocular, or intraspinal bleeding, or requiring surgical treatment, or leading to a transfusion of 2 units or more, or leading to a fall in hemoglobin of 20g/L or more</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Fatal or Life-threatening Major Bleeding Events</title>
          <description>Retroperitoneal, intracranial, intraocular, or intraspinal bleeding, or requiring surgical treatment, or leading to a transfusion of 2 units or more, or leading to a fall in hemoglobin of 20g/L or more</description>
          <population>All treated patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="105"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Minor/Relevant Bleeding Events</title>
        <description>Haematuria, rectal bleeding, gingival bleeding, skin hematoma of 25cm^2 or more, nose bleed of more than 5 minutes duration, bleeding leading to a hospitalization, leading to a transfusion of less than 2 units or any other clinically relevant bleeding</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons were performed, due to the small number of events per group</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Minor/Relevant Bleeding Events</title>
          <description>Haematuria, rectal bleeding, gingival bleeding, skin hematoma of 25cm^2 or more, nose bleed of more than 5 minutes duration, bleeding leading to a hospitalization, leading to a transfusion of less than 2 units or any other clinically relevant bleeding</description>
          <population>All treated patients. No statistical comparisons were performed, due to the small number of events per group</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="105"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="9"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="6"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="3"/>
                    <measurement group_id="O10" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Minor/Nuisance Bleeding Events</title>
        <description>All bleeding events not fulfilling one of the criteria for major bleeding event or minor/relevant bleeding events.</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons were performed, due to the small number of events per group</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Minor/Nuisance Bleeding Events</title>
          <description>All bleeding events not fulfilling one of the criteria for major bleeding event or minor/relevant bleeding events.</description>
          <population>All treated patients. No statistical comparisons were performed, due to the small number of events per group</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="100"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="105"/>
                <count group_id="O8" value="34"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="5"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="7"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thromboembolic Events: Composite Endpoint</title>
        <description>Combination of ischemic stroke (fatal or non fatal), transient ischemic attack, systemic thromboembolism, myocardial infarction (fatal or non fatal), other major adverse cardiac event and all cause mortality</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thromboembolic Events: Composite Endpoint</title>
          <description>Combination of ischemic stroke (fatal or non fatal), transient ischemic attack, systemic thromboembolism, myocardial infarction (fatal or non fatal), other major adverse cardiac event and all cause mortality</description>
          <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Thromboembolic Events: Ischemic Stroke</title>
        <description>Occurence of an ischemic stroke (fatal or non-fatal)</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Thromboembolic Events: Ischemic Stroke</title>
          <description>Occurence of an ischemic stroke (fatal or non-fatal)</description>
          <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="19"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="98"/>
                    <measurement group_id="O8" value="33"/>
                    <measurement group_id="O9" value="30"/>
                    <measurement group_id="O10" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Fatal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thromboembolic Events: Number of Participants With Transient Ischemic Attack</title>
        <description>Occurence of a transient ischemic attack</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Thromboembolic Events: Number of Participants With Transient Ischemic Attack</title>
          <description>Occurence of a transient ischemic attack</description>
          <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thromboembolic Events: Number of Participants With Systemic Thromboembolism</title>
        <description>Occurence of a systemic thromboembolism</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Thromboembolic Events: Number of Participants With Systemic Thromboembolism</title>
          <description>Occurence of a systemic thromboembolism</description>
          <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thromboembolic Events: Number of Participants With Myocardial Infarction</title>
        <description>Occurence of a myocardial infarction</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Thromboembolic Events: Number of Participants With Myocardial Infarction</title>
          <description>Occurence of a myocardial infarction</description>
          <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>None</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="99"/>
                    <measurement group_id="O5" value="34"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="98"/>
                    <measurement group_id="O8" value="33"/>
                    <measurement group_id="O9" value="30"/>
                    <measurement group_id="O10" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fatal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Fatal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Both</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thromboembolic Events: Number of Participants With Other Major Cardiac Events</title>
        <description>Occurence of other major adverse cardiac events</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Thromboembolic Events: Number of Participants With Other Major Cardiac Events</title>
          <description>Occurence of other major adverse cardiac events</description>
          <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Thromboembolic Events: Number of Participants Who Died</title>
        <description>Occurence of death by all causes</description>
        <time_frame>12 weeks</time_frame>
        <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Thromboembolic Events: Number of Participants Who Died</title>
          <description>Occurence of death by all causes</description>
          <population>All randomized patients. No statistical comparisons were performed, due to the extremely small number of events.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>D-dimer: Difference From Baseline</title>
        <description>Difference in D-dimer from baseline to last available value</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>All randomised patients, only per-protocol data included.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>D-dimer: Difference From Baseline</title>
          <description>Difference in D-dimer from baseline to last available value</description>
          <population>All randomised patients, only per-protocol data included.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="55"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="87"/>
                <count group_id="O5" value="29"/>
                <count group_id="O6" value="32"/>
                <count group_id="O7" value="88"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="29"/>
                <count group_id="O10" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.3" spread="65.4"/>
                    <measurement group_id="O2" value="12.3" spread="25.3"/>
                    <measurement group_id="O3" value="50.2" spread="182.8"/>
                    <measurement group_id="O4" value="8.1" spread="41.6"/>
                    <measurement group_id="O5" value="29.1" spread="90.4"/>
                    <measurement group_id="O6" value="8.6" spread="49.2"/>
                    <measurement group_id="O7" value="4.2" spread="95.8"/>
                    <measurement group_id="O8" value="11.3" spread="82.2"/>
                    <measurement group_id="O9" value="-7.9" spread="40.9"/>
                    <measurement group_id="O10" value="-5.8" spread="50.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Group comparison of differences from baseline to last available value</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0357</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Soluble Fibrin: Difference From Baseline</title>
        <description>Difference from baseline to visit 7</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>All randomised patients, only per-protocol data included.</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Soluble Fibrin: Difference From Baseline</title>
          <description>Difference from baseline to visit 7</description>
          <population>All randomised patients, only per-protocol data included.</population>
          <units>µg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="88"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="24"/>
                <count group_id="O7" value="83"/>
                <count group_id="O8" value="27"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="22.0"/>
                    <measurement group_id="O2" value="0.9" spread="2.3"/>
                    <measurement group_id="O3" value="1.2" spread="8.4"/>
                    <measurement group_id="O4" value="0.3" spread="5.1"/>
                    <measurement group_id="O5" value="-2.0" spread="9.9"/>
                    <measurement group_id="O6" value="-1.3" spread="8.8"/>
                    <measurement group_id="O7" value="2.3" spread="26.8"/>
                    <measurement group_id="O8" value="-0.7" spread="4.6"/>
                    <measurement group_id="O9" value="-1.9" spread="12.0"/>
                    <measurement group_id="O10" value="0.1" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
            </group_id_list>
            <groups_desc>Group comparison of differences from baseline to week 12</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26711</p_value>
            <method>Kruskal-Wallis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>11-dehydrothromboxane B2 (TXB2): Difference From Baseline</title>
        <description>Difference from baseline to visit 7</description>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons due to high variability</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>11-dehydrothromboxane B2 (TXB2): Difference From Baseline</title>
          <description>Difference from baseline to visit 7</description>
          <population>All treated patients. No statistical comparisons due to high variability</population>
          <units>pg/mg Creatinine</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
                <count group_id="O2" value="17"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="73"/>
                <count group_id="O5" value="25"/>
                <count group_id="O6" value="27"/>
                <count group_id="O7" value="73"/>
                <count group_id="O8" value="25"/>
                <count group_id="O9" value="25"/>
                <count group_id="O10" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596.5" spread="2896.3"/>
                    <measurement group_id="O2" value="-1816.8" spread="2186.1"/>
                    <measurement group_id="O3" value="-2779.8" spread="2953.3"/>
                    <measurement group_id="O4" value="922.0" spread="3874.0"/>
                    <measurement group_id="O5" value="-1988.6" spread="2187.5"/>
                    <measurement group_id="O6" value="-1125.9" spread="3566.6"/>
                    <measurement group_id="O7" value="1059.7" spread="2216.8"/>
                    <measurement group_id="O8" value="-1822.6" spread="2381.7"/>
                    <measurement group_id="O9" value="-1337.8" spread="2279.2"/>
                    <measurement group_id="O10" value="203.5" spread="2109.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ecarin Clotting Time (ECT): Difference From Baseline</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons due to high variability</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Ecarin Clotting Time (ECT): Difference From Baseline</title>
          <population>All treated patients. No statistical comparisons due to high variability</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="94"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="86"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="27"/>
                <count group_id="O10" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" spread="8.2"/>
                    <measurement group_id="O2" value="12.0" spread="10.7"/>
                    <measurement group_id="O3" value="12.0" spread="9.6"/>
                    <measurement group_id="O4" value="31.9" spread="26.2"/>
                    <measurement group_id="O5" value="42.5" spread="29.2"/>
                    <measurement group_id="O6" value="32.7" spread="23.1"/>
                    <measurement group_id="O7" value="63.6" spread="44.8"/>
                    <measurement group_id="O8" value="70.8" spread="60.3"/>
                    <measurement group_id="O9" value="74.0" spread="70.5"/>
                    <measurement group_id="O10" value="3.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Activated Partial Thromboplastin Time (aPTT): Difference From Baseline</title>
        <time_frame>baseline and 12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons due to high variability</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Activated Partial Thromboplastin Time (aPTT): Difference From Baseline</title>
          <population>All treated patients. No statistical comparisons due to high variability</population>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="92"/>
                <count group_id="O5" value="33"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="87"/>
                <count group_id="O8" value="29"/>
                <count group_id="O9" value="27"/>
                <count group_id="O10" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.4" spread="5.6"/>
                    <measurement group_id="O2" value="8.3" spread="6.1"/>
                    <measurement group_id="O3" value="8.8" spread="9.4"/>
                    <measurement group_id="O4" value="13.5" spread="18.3"/>
                    <measurement group_id="O5" value="24.9" spread="26.1"/>
                    <measurement group_id="O6" value="14.5" spread="11.5"/>
                    <measurement group_id="O7" value="25.0" spread="12.4"/>
                    <measurement group_id="O8" value="23.4" spread="12.7"/>
                    <measurement group_id="O9" value="27.2" spread="24.2"/>
                    <measurement group_id="O10" value="8.8" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Plasma Concentration of Dabigatran (BIBR 953)</title>
        <description>The values of the trough plasma concentration of dabigatran (BIBR 953) are the by-patient geometric means of week 1, 4 and 12.</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated patients</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Plasma Concentration of Dabigatran (BIBR 953)</title>
          <description>The values of the trough plasma concentration of dabigatran (BIBR 953) are the by-patient geometric means of week 1, 4 and 12.</description>
          <population>All treated patients</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="97"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.1" spread="16.6"/>
                    <measurement group_id="O2" value="30.4" spread="16.6"/>
                    <measurement group_id="O3" value="31.8" spread="20.0"/>
                    <measurement group_id="O4" value="82.8" spread="54.3"/>
                    <measurement group_id="O5" value="103.2" spread="69.0"/>
                    <measurement group_id="O6" value="90.1" spread="52.5"/>
                    <measurement group_id="O7" value="188.0" spread="117.3"/>
                    <measurement group_id="O8" value="203.7" spread="123.9"/>
                    <measurement group_id="O9" value="207.6" spread="108.7"/>
                    <measurement group_id="O10" value="NA"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase of Aspartat-Aminotransferase (AST) to &gt;2*Baseline</title>
        <description>Increase of AST to more than two times the baseline value</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons due to extremely small number of cases</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase of Aspartat-Aminotransferase (AST) to &gt;2*Baseline</title>
          <description>Increase of AST to more than two times the baseline value</description>
          <population>All treated patients. No statistical comparisons due to extremely small number of cases</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="93"/>
                    <measurement group_id="O5" value="32"/>
                    <measurement group_id="O6" value="31"/>
                    <measurement group_id="O7" value="95"/>
                    <measurement group_id="O8" value="31"/>
                    <measurement group_id="O9" value="30"/>
                    <measurement group_id="O10" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase of Alkaline Phosphatase (AP) to &gt;2*Baseline</title>
        <description>Increase of AP to more than two times the baseline value</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons due to extremely small number of cases</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase of Alkaline Phosphatase (AP) to &gt;2*Baseline</title>
          <description>Increase of AP to more than two times the baseline value</description>
          <population>All treated patients. No statistical comparisons due to extremely small number of cases</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="97"/>
                    <measurement group_id="O8" value="32"/>
                    <measurement group_id="O9" value="29"/>
                    <measurement group_id="O10" value="69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase of Bilirubin to &gt;2*Baseline</title>
        <description>Increase of Bilirubin to more than two times the baseline value</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons due to extremely small number of cases</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase of Bilirubin to &gt;2*Baseline</title>
          <description>Increase of Bilirubin to more than two times the baseline value</description>
          <population>All treated patients. No statistical comparisons due to extremely small number of cases</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="25"/>
                    <measurement group_id="O4" value="86"/>
                    <measurement group_id="O5" value="31"/>
                    <measurement group_id="O6" value="33"/>
                    <measurement group_id="O7" value="88"/>
                    <measurement group_id="O8" value="29"/>
                    <measurement group_id="O9" value="29"/>
                    <measurement group_id="O10" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="13"/>
                    <measurement group_id="O5" value="3"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="3"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Increase of Alanine-Aminotransferase (ALT) to &gt;2*Baseline</title>
        <description>Number of Participants with Increase of ALT to more than two times the baseline value</description>
        <time_frame>12 weeks</time_frame>
        <population>All treated patients. No statistical comparisons due to extremely small number of cases</population>
        <group_list>
          <group group_id="O1">
            <title>BIBR 1048 50 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O2">
            <title>BIBR 1048 50 mg b.i.d + ASA 81 mg q.d.</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O3">
            <title>BIBR 1048 50 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O4">
            <title>BIBR 1048 150 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O5">
            <title>BIBR 1048 150 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O6">
            <title>BIBR 1048 150 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O7">
            <title>BIBR 1048 300 mg b.i.d</title>
            <description>bid (twice daily) oral</description>
          </group>
          <group group_id="O8">
            <title>BIBR 1048 300 mg b.i.d + ASA 81 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O9">
            <title>BIBR 1048 300 mg b.i.d + ASA 325 mg qd</title>
            <description>bid (twice daily) oral + qd (once daily) oral</description>
          </group>
          <group group_id="O10">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>qd (once daily) oral</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Increase of Alanine-Aminotransferase (ALT) to &gt;2*Baseline</title>
          <description>Number of Participants with Increase of ALT to more than two times the baseline value</description>
          <population>All treated patients. No statistical comparisons due to extremely small number of cases</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="99"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="33"/>
                <count group_id="O7" value="98"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="30"/>
                <count group_id="O10" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="1"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="95"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="32"/>
                    <measurement group_id="O7" value="93"/>
                    <measurement group_id="O8" value="31"/>
                    <measurement group_id="O9" value="30"/>
                    <measurement group_id="O10" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Yes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="4"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="0"/>
                    <measurement group_id="O10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Severity of Adverse Events</title>
        <description>Total number of patients with any adverse event of worst intensity 'mild', 'moderate' and 'severe'.</description>
        <time_frame>12 weeks</time_frame>
        <population>Treated patients(Numbers of patients for adverse events are counted for each treatment and are in their sum greater than the total number of patients randomized as 14 patients on Dabigatran with ASA changed treatment,12 patients down titrated Dabigatran bid to qd of which one did the down titration at the same time as the stop of the ASA treatment)</population>
        <group_list>
          <group group_id="O1">
            <title>D50bid</title>
            <description>Dabigatran 50 mg twice daily</description>
          </group>
          <group group_id="O2">
            <title>D50qd</title>
            <description>Dabigatran 50 mg once daily</description>
          </group>
          <group group_id="O3">
            <title>D50bid + ASA81qd</title>
            <description>Dabigatran 50 mg twice daily + ASA 81 mg once daily</description>
          </group>
          <group group_id="O4">
            <title>D50bid + ASA325qd</title>
            <description>Dabigatran 50 mg twice daily + ASA 325 mg once daily</description>
          </group>
          <group group_id="O5">
            <title>D150bid</title>
            <description>Dabigatran 150 mg twice daily</description>
          </group>
          <group group_id="O6">
            <title>D150qd</title>
            <description>Dabigatran 150 mg once daily</description>
          </group>
          <group group_id="O7">
            <title>D150bid + ASA81qd</title>
            <description>Dabigatran 150 mg twice daily + ASA 81 mg once daily</description>
          </group>
          <group group_id="O8">
            <title>D150qd + ASA81qd</title>
            <description>Dabigatran 150 mg once daily + ASA 81 mg once daily</description>
          </group>
          <group group_id="O9">
            <title>D150bid + ASA325qd</title>
            <description>Dabigatran 150 mg twice daily + ASA 325 mg once daily</description>
          </group>
          <group group_id="O10">
            <title>D150qd + ASA325qd</title>
            <description>Dabigatran 150 mg once daily + ASA 325 mg once daily</description>
          </group>
          <group group_id="O11">
            <title>D300bid</title>
            <description>Dabigatran 300 mg twice daily</description>
          </group>
          <group group_id="O12">
            <title>D300qd</title>
            <description>Dabigatran 300 mg once daily</description>
          </group>
          <group group_id="O13">
            <title>D300bid + ASA81qd</title>
            <description>Dabigatran 300 mg twice daily + ASA 81 mg once daily</description>
          </group>
          <group group_id="O14">
            <title>D300qd + ASA81qd</title>
            <description>Dabigatran 300 mg once daily + ASA 81 mg once daily</description>
          </group>
          <group group_id="O15">
            <title>D300bid + ASA325qd</title>
            <description>Dabigatran 300 mg twice daily + ASA 325 mg once daily</description>
          </group>
          <group group_id="O16">
            <title>D300qd + ASA325qd</title>
            <description>Dabigatran 300 mg once daily + ASA 325 mg once daily</description>
          </group>
          <group group_id="O17">
            <title>Warfarin, Dosed to Target INR 2.0 to 3.0</title>
            <description>Warfarin once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Severity of Adverse Events</title>
          <description>Total number of patients with any adverse event of worst intensity 'mild', 'moderate' and 'severe'.</description>
          <population>Treated patients(Numbers of patients for adverse events are counted for each treatment and are in their sum greater than the total number of patients randomized as 14 patients on Dabigatran with ASA changed treatment,12 patients down titrated Dabigatran bid to qd of which one did the down titration at the same time as the stop of the ASA treatment)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="27"/>
                <count group_id="O5" value="100"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="36"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="33"/>
                <count group_id="O10" value="1"/>
                <count group_id="O11" value="105"/>
                <count group_id="O12" value="3"/>
                <count group_id="O13" value="34"/>
                <count group_id="O14" value="2"/>
                <count group_id="O15" value="30"/>
                <count group_id="O16" value="1"/>
                <count group_id="O17" value="70"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="16"/>
                    <measurement group_id="O5" value="54"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="23"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="17"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="47"/>
                    <measurement group_id="O12" value="1"/>
                    <measurement group_id="O13" value="23"/>
                    <measurement group_id="O14" value="2"/>
                    <measurement group_id="O15" value="23"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                    <measurement group_id="O5" value="19"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="9"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="4"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="23"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="5"/>
                    <measurement group_id="O14" value="1"/>
                    <measurement group_id="O15" value="11"/>
                    <measurement group_id="O16" value="1"/>
                    <measurement group_id="O17" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="4"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="0"/>
                    <measurement group_id="O9" value="1"/>
                    <measurement group_id="O10" value="0"/>
                    <measurement group_id="O11" value="6"/>
                    <measurement group_id="O12" value="0"/>
                    <measurement group_id="O13" value="1"/>
                    <measurement group_id="O14" value="0"/>
                    <measurement group_id="O15" value="2"/>
                    <measurement group_id="O16" value="0"/>
                    <measurement group_id="O17" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <desc>Note that it was foreseen per protocol that all treatments were possibly to be down-titrated to BIBR 1048 q.d.; criteria included creatinine clearance and aPTT. Events are counted to the treatment on which they occurred.</desc>
      <group_list>
        <group group_id="E1">
          <title>D50bid</title>
          <description>Dabigatran 50 mg twice daily</description>
        </group>
        <group group_id="E2">
          <title>D50qd</title>
          <description>Dabigatran 50 mg once daily</description>
        </group>
        <group group_id="E3">
          <title>D50bid + ASA81qd</title>
          <description>Dabigatran 50 mg twice daily + ASA 81 mg once daily</description>
        </group>
        <group group_id="E4">
          <title>D50bid + ASA325qd</title>
          <description>Dabigatran 50 mg twice daily + ASA 325 mg once daily</description>
        </group>
        <group group_id="E5">
          <title>D150bid</title>
          <description>Dabigatran 150 mg twice daily</description>
        </group>
        <group group_id="E6">
          <title>D150qd</title>
          <description>Dabigatran 150 mg once daily</description>
        </group>
        <group group_id="E7">
          <title>D150bid + ASA81qd</title>
          <description>Dabigatran 150 mg twice daily + ASA 81 mg once daily</description>
        </group>
        <group group_id="E8">
          <title>D150qd + ASA81qd</title>
          <description>Dabigatran 150 mg once daily + ASA 81 mg once daily</description>
        </group>
        <group group_id="E9">
          <title>D150bid + ASA325qd</title>
          <description>Dabigatran 150 mg twice daily + ASA 325 mg once daily</description>
        </group>
        <group group_id="E10">
          <title>D150qd + ASA325qd</title>
          <description>Dabigatran 150 mg once daily + ASA 325 mg once daily</description>
        </group>
        <group group_id="E11">
          <title>D300bid</title>
          <description>Dabigatran 300 mg twice daily</description>
        </group>
        <group group_id="E12">
          <title>D300qd</title>
          <description>Dabigatran 300 mg once daily</description>
        </group>
        <group group_id="E13">
          <title>D300bid + ASA81qd</title>
          <description>Dabigatran 300 mg twice daily + ASA 81 mg once daily</description>
        </group>
        <group group_id="E14">
          <title>D300qd + ASA81qd</title>
          <description>Dabigatran 300 mg once daily + ASA 81 mg once daily</description>
        </group>
        <group group_id="E15">
          <title>D300bid + ASA325qd</title>
          <description>Dabigatran 300 mg twice daily + ASA 325 mg once daily</description>
        </group>
        <group group_id="E16">
          <title>D300qd + ASA325qd</title>
          <description>Dabigatran 300 mg once daily + ASA 325 mg once daily</description>
        </group>
        <group group_id="E17">
          <title>Warfarin</title>
          <description>Warfarin once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="4" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Lower gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Oesophageal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Implantable defibrillator malfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Blood pressure systolic inspiratory decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal infarct</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin discolouration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Peripheral embolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 7.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="43" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="19" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="15" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="35" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="20" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="18" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="22" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Gingival bleeding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Mouth haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="3" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Sensation of pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="6" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="1" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="5" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="2" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Exanthem</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="0" subjects_at_risk="70"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="59"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="36"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="33"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E14" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E15" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E16" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E17" subjects_affected="1" subjects_at_risk="70"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any publication of the result of this trial must be consistent with the Boehringer Ingelheim publication policy. The rights of the investigator and of the sponsor with regard to publication of the results of this trial are described in the investigator contract.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim Call Center</name_or_title>
      <organization>Boehringer Ingelheim Pharmaceuticals</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

